Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Karen Baranowski"'
Autor:
Ulka N. Vaishampayan, Lawrence E. Flaherty, Jawana M. Lawhorn-Crews, Karen Baranowski, Lance K. Heilbrun, Daryn Smith, Anthony F. Shields
Publikováno v:
Investigational New Drugs. 25:69-75
To evaluate the toxicity and efficacy of interferon and thalidomide combination in a phase II clinical trial.Eligibility included metastatic renal cancer with a maximum of two prior regimens, performance status of 0-2 and adequate renal, hepatic and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96477a9b75b2bdf8b79277344d75e922
https://doi.org/10.1007/s10637-006-9005-8
https://doi.org/10.1007/s10637-006-9005-8
Autor:
Shin Ogita, Lance K. Heilbrun, Karen Baranowski, Ulka N. Vaishampayan, Elisabeth I. Heath, Joseph A. Fontana, Daryn Smith, Stacy Freeman, Sheela Tejwani
Publikováno v:
ISRN Oncology
Introduction/Background. Nonmetastatic castrate resistant prostate cancer (CRPC) is a challenging disease state. The objective of this study was to evaluate the efficacy and tolerability of bevacizumab in nonmetastatic CRPC patients. Patients. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12bebe4b64fe8e14095091535a99806c
Autor:
Daryn Smith, Karen Baranowski, Brenda Dickow, Ulka N. Vaishampayan, Lance K. Heilbrun, S. Marur, Samir Alhasan, James F. Eliason
Publikováno v:
Urology. 72(4)
Objectives To evaluate the toxicity and efficacy of capecitabine and weekly docetaxel in a phase II clinical trial. Methods Eligibility included metastatic renal cancer with a maximum of 2 prior regimens, performance status of 0-2, and adequate renal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f175d003c5ef4757165ca0581951f2e
https://pubmed.ncbi.nlm.nih.gov/18692873
https://pubmed.ncbi.nlm.nih.gov/18692873
Autor:
Lance K. Heilbrun, Ulka N. Vaishampayan, Elisabeth I. Heath, Daryn Smith, Karen Baranowski, Jiahuai Tan, Joseph A. Fontana
Publikováno v:
Journal of Clinical Oncology. 30:415-415
415 Background: Pazopanib is an oral tyrosine kinase inhibitor and is currently approved for treatment of patients with advanced or mRCC in the first-line, or second-line setting, after progression on cytokine therapy. No reports of efficacy and safe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cccba1b99ad296dba50ea39c2e7d9c0f
https://doi.org/10.1200/jco.2012.30.5_suppl.415
https://doi.org/10.1200/jco.2012.30.5_suppl.415
Phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer (CRPC)
Autor:
Sheela Tejwani, S. Ogita, Lance K. Heilbrun, Joseph A. Fontana, Elisabeth I. Heath, S. Freeman, Ulka N. Vaishampayan, Daryn Smith, Karen Baranowski
Publikováno v:
Journal of Clinical Oncology. 29:33-33
33 Background: To this day, no therapy has proven efficacy in the clinical management of PSA relapse non-metastatic CRPC. Investigating novel therapeutic agents that will induce a PSA response, and delay progression to overt metastases is of paramoun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::612133c179d566436fd85dc3bcdf2e76
https://doi.org/10.1200/jco.2011.29.7_suppl.33
https://doi.org/10.1200/jco.2011.29.7_suppl.33
Autor:
Brenda Dickow, Lance K. Heilbrun, J. E. Pontes, Ulka N. Vaishampayan, Michael L. Cher, Karen Baranowski, Daryn Smith, Isaac J. Powell, Elisabeth I. Heath, Joseph A. Fontana
Publikováno v:
Journal of Clinical Oncology. 29:152-152
152 Background: Satraplatin is an oral platinum that has demonstrated efficacy and tolerability in metastatic CRPC. Bevacizumab has revealed safety and efficacy in advanced prostate cancer, and synergy was noted between platinum based chemotherapy an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b18ba7e26809ba651a2321a7dcca69f9
https://doi.org/10.1200/jco.2011.29.7_suppl.152
https://doi.org/10.1200/jco.2011.29.7_suppl.152
Autor:
Isaac J. Powell, Brenda Dickow, Karen Baranowski, Lance K. Heilbrun, Joseph A. Fontana, Ulka N. Vaishampayan, Daryn Smith, Elisabeth I. Heath
Publikováno v:
Journal of Clinical Oncology. 27:e16028-e16028
e16028 Background: In metastatic CRPC, second line therapy after docetaxel, remains a currently unmet need. Based on the efficacy and tolerability of S and B in prostate cancer, and the clinical synergy noted between chemotherapy and B, a phase II tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63f3b02007517b1459b3039e6009b99f
https://doi.org/10.1200/jco.2009.27.15_suppl.e16028
https://doi.org/10.1200/jco.2009.27.15_suppl.e16028
Autor:
Lance Heilbrun, Anthony Shields, Jawana Lawhorn-Crews, Karen Baranowski, Daryn Smith, Lawrence Flaherty
Publikováno v:
Investigational New Drugs; Feb2007, Vol. 25 Issue 1, p69-75, 7p
Publikováno v:
The Nurse Practitioner. 7:20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c74f515c624d785beb19a07116557c51
https://doi.org/10.1097/00006205-198202000-00004
https://doi.org/10.1097/00006205-198202000-00004